• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Teva Pharmaceutical Industries - Articles and news items


Teva’s severe eosinophilic asthma drug Cinqaero wins EU approval

Industry news / 18 August 2016 / Caroline Richards, Editor, European Pharmaceutical Review & Drug Target Review

Cinqaero is a humanised interleukin-5 antagonist monoclonal antibody (IgG4 kappa) for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +